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Victoria, Canada.BACKGROUND The beneﬁts of implantable cardioverter-
deﬁbrillators (ICDs) have been well demonstrated in many clinical
trials, and ICD shocks for ventricular tachyarrhythmias save lives.
However, inappropriate and unnecessary shock delivery remains a
signiﬁcant clinical issue with considerable consequences for
patients and the healthcare system.
OBJECTIVE The purpose of the PainFree SmartShock Technology
(SST) study was to investigate new-generation ICDs to reduce
inappropriate and unnecessary shocks through novel discrimination
algorithms with modern programming strategies.
METHODS This prospective, multicenter clinical trial enrolled 2790
patients with approved indication for ICD implantation (79% male,
mean age 65 years; 69% primary prevention indication, 27% single-
chamber ICD, 33% replacement or upgrade). Patients were followed
for a minimum of 12 months, and mean follow-up was 22 months.
The primary end-point of the study was the percentage of patients
remaining free of inappropriate shocks at 1 year postimplant,
analyzed separately for dual/triple-chamber ICDs (N ¼ 2019) and
single-chamber ICDs (N ¼ 751).
RESULTS The inappropriate shock rate at 1 year was 1.5% for
patients with dual/triple-chamber ICDs and 2.5% for patients withThis study was funded by Medtronic Inc, Minneapolis, Minnesota. Dr.
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shock rate was 2.8% for patients with dual-/triple chamber ICDs and
3.7% for those with single-chamber ICDs. The most common cause of
an inappropriate shock in both groups was atrial ﬁbrillation or ﬂutter.
CONCLUSION In a large patient cohort receiving ICDs for primary
or secondary prevention, the adoption of novel enhanced detection
algorithms in conjunction with routine implementation of modern
programming strategies led to a very low inappropriate shock rate.
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Implantable cardioverter-deﬁbrillator (ICD) therapy is the
standard of care for secondary prevention of sudden cardiac
death and for primary prevention of cardiac arrest in
appropriately selected patients with established risk.1
Although ICD shocks are lifesaving in the case of sustained
ventricular tachyarrhythmias, shocks can also be delivered
unnecessarily for nonsustained episodes or inappropriately
for supraventricular arrhythmias, nonarrhythmic noise, or
artifacts.2,3 These avoidable ICD shocks result in unneces-
sary hospital admissions and may have a negative impact on
patient quality of life4–6 as well as on morbidity and
mortality.7,8
Although the reported frequency of ICD shocks varies
according to patient population, device type, and speciﬁc
ICD programming, a substantial proportion of patients
consistently receive inappropriate shocks after ICD implan-
tation. Recent studies have reported inappropriate shocks
rates of up to 10%, but have largely excluded single-chamber
devices that have been associated with inappropriate therapy
rates between 14% and 27%.9–12 Shock reduction strategies
have included selective implantation of atrial leads for
improved supraventricular tachycardia (SVT) diagnosis,
widespread use of empiric antitachycardia pacing (ATP)
for relatively rapid arrhythmias, strategic programming to
delay ICD detection or treatment, and development of
improved arrhythmia discrimination algorithms.
A strategy for reducing inappropriate shocks combining
improved arrhythmia discrimination algorithms and longer
detection times was previously evaluated through the use of
archived patient electrograms and “virtual ICD” computer
modeling.13 In the PainFree SST (SmartShock Technology)
study, we sought to prospectively validate the prediction that
a novel suite of new detection algorithms in conjunction with
routine implementation of a proven programming strategy
would improve freedom from inappropriate shocks in a large
and heterogeneous “real-world” population of ICD patients.
Methods
Study design
The study design of the PainFree SST trial has previously
been described.14 In brief, the PainFree SST study was a
prospective, multicenter clinical trial conducted in 2 consec-
utive phases. All subjects were followed until study closure
but not less than 1 year. Total study duration was 4 years,
from September 2009 until August 2013. After implantation,
subjects were required to have a follow-up visit every 6
months. Data were collected at the time of enrollment, at
scheduled and unscheduled follow-up visits, and at
study exit.
Study population
Patients were eligible for the study if they had a clinical
indication for an ICD for either primary or secondary
prevention of sudden cardiac death and intended to receive
a single-chamber or, dual/triple-chamber Protecta device(Medtronic Inc, Minneapolis, MN). This included new
implants, system upgrades, and generator replacements.
Exclusion criteria included, among others, participation in
another study that could confound results, life expectancy
less than 12 months, or the presence of a mechanical
tricuspid heart valve. The study was performed in compli-
ance with the Declaration of Helsinki. The institutional
review board of each participating center approved the study
protocol, and all patients gave written informed consent.
Study end-points
The primary study end-point was the percentage of patients
receiving at least 1 inappropriate shock at 12 months.
Secondary end-points included the percentage of patients
receiving any inappropriate device therapy (ie, shocks and/or
overdrive pacing (ATP)) at 12 months, the causes of
inappropriate shocks, the incidence of appropriate device
therapy, and evaluation of any undertreatment of ventricular
arrhythmias. All-cause mortality also was reported.
Algorithm description
SmartShock Technology consists of 6 discrimination algo-
rithms that are activated by the device when rate-based
arrhythmia detection criteria are met in order to distinguish
between true ventricular arrhythmias and other rhythms. This
technology has demonstrated clinical safety and ventricular
ﬁbrillation (VF) detection efﬁcacy and sensitivity.15 Detailed
descriptions of the new and updated algorithms can be found
elsewhere.14 (1) Wavelet morphology algorithms were
integrated with atrioventricular timing discrimination (PR
Logic) in dual/triple-chamber ICDs to help differentiate
ventricular tachycardia (VT) from SVT based on QRS
morphology. This discrimination applies to all VT with rates
slower than a programmable limiting rate (SVT Limit). (2)
The nominal SVT Limit has been changed from 320 to 260
ms to allow SVT discriminators to withhold detection and
therapy for atrial rhythms that are faster than the VF
detection interval. (3) Conﬁrmationþ improves recognition
of VT/VF termination to prevent inappropriate shock by
using conﬁrmation intervals based on ventricular cycle
length þ 60 ms instead of the slowest programmed therapy
zone. (4) T-Wave Oversensing algorithm withholds detec-
tion and therapy when T-wave oversensing is occurring
based on information from the sensing channel and a parallel
signal path that attenuates lower-frequency signals such as
T-waves while minimally attenuating R waves. (5) Lead
Noise Discrimination algorithm discriminates sensed rhythms
that are due to lead noise from those due to VT/VF and
provides the ability to withhold therapy delivery. (6) RV Lead
Integrity Alert provides early indication of potential lead
fracture by an audible alert and automatically extends VF
number of intervals to detect (NID) to 30/40 (if it was less).
Device programming
VF zones were programmed with a detection interval of 320
ms, and programming of a VT therapy zone was left up to the
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grammed ON, per the nominal “out of box” settings of the
device. SVT discrimination algorithms were active for median
ventricular intervalsZ260ms. In primary prevention patients,
the NID was programmed at 30/40, requiring 30 of 40
subsequent intervals to be o320 ms, which is clinically
proven to safely reduce shocks.16 The secondary prevention
patients were randomized between NID 30/40 and 18/24 with
further analysis to be reported at a later time. ATP during
charging was programmed in the VF zone. VT detection and
therapy was left to the physician’s discretion. Further details
are described in the design paper of this trial.14
Rhythm classiﬁcation
All ICDs were programmed to store a near-ﬁeld and a far-ﬁeld
electrogram (EGM) for spontaneous device-detected episodes.
Episodes were adjudicated by an episode review committee
(ERC) comprising 9 independent physicians who were not
study investigators (Appendix B). Each spontaneous episode
with stored EGM was reviewed by 2 ERC members and by a
third reviewer in the case of disagreement. If concordance was
not achieved between 2 of 3 reviewers, the episode was
reviewed by the full ERC to reach consensus. All episodes
resulting in therapy delivery were classiﬁed as appropriate or
inappropriate. An episode was considered inappropriate when
any therapy was delivered in a rhythm that was not a true
ventricular arrhythmia, including a nonsustained episode that
self-terminated before shock. Untreated episodes also were
adjudicated to assess sensitivity.
Statistical analysis
Continuous variables are reported with mean and standard
deviation and categorical variables with count and percent-
age. Therapy rates were analyzed using competing risks
survival analysis methods, accounting for death as a com-
peting risk. Therapy incidence rates were estimated using
cumulative incidence functions17 and reported with 95%
conﬁdence interval (CI). Incidence rates thus represent the
percentage of patients with at least 1 therapy event in the
speciﬁed time window. All inappropriately shocked episodes
were included in the analysis. A sensitivity analysis was
performed by counting shocked episodes with incomplete
data (only EGM missing) as inappropriate. The relationship
between inappropriate shocks and patient baseline character-
istics was analyzed using a multivariable Fine and Gray
regression model.18 Age and left ventricular ejection fraction
(LVEF) were included in the model as continuous variables,
but QRS duration was dichotomized with a cutoff value of
120 ms because of observed nonlinearity of the effect. Other
variables included were device type, gender, indication
(primary vs secondary prevention), previous device, history
of myocardial infarction, atrial ﬁbrillation (AF), VT, and the
prescription of antiarrhythmic drugs. There were missing
values for gender (0.2%), age (0.2%), LVEF (7.4%), QRS
duration (12.3%), and indication (0.2%). Multiple imputa-
tion using the fully conditional speciﬁcation method wasused to create 10 imputed datasets that were analyzed
separately.19 Results were combined using the Rubin rule.
Statistical comparison of subgroups deﬁned by programming
of VT therapies used a 2-sided Gray test.17
Episodes that met ventricular rate criteria, but had device
therapy withheld due to the discrimination algorithms were
all reviewed by the ERC and classiﬁed as appropriately or
inappropriately rejected. Relative sensitivity was calculated
as the quotient between the number of true VT/VF episodes
that appropriately received therapy and the number of all true
VT/VF episodes.
The study was designed to include at least 1131 patients
with dual/triple-chamber devices in order to estimate the
inappropriate shock rate at 1 year postimplant with 1%
precision. This was based on the assumption that the
inappropriate shock rate would be 4%.3,14 Similarly, inclu-
sion of at least 610 patients with single-chamber devices
would achieve 2% precision in case of a true inappropriate
shock rate of 7.5% at 1 year. P o .05 was considered
signiﬁcant. All analyses were performed with SAS versions
9.3 and 9.4 (SAS Institute Inc, Cary, NC).
Results
Study population
Between September 2009 and August 2012, a total of 2790
patients were enrolled by 126 centers in North and South
America, Europe, Asia, and Africa. Twenty patients were
excluded from analysis, because they did not meet the
eligibility criteria; 1 patient did not sign consent, 1 patient
participated in a confounding trial, 8 patients did not have an
implant attempted, 5 patients failed implant, and 5 patients
received a device other than the Protecta. Baseline character-
istics for the remaining 2770 patients, including 751 recip-
ients of a single-chamber, 948 of a dual-chamber, and 1,071
of a triple-chamber ICD, are given in Table 1.
Patients were followed for a mean of 22 9 months with
min–max range of 0 to 46 months for dual/triple-chamber
ICDs and 0 to 35 months for single-chamber ICDs. During
this period, 230 patients died and 438 patients exited the
study early. Postimplant device data were available for 2598
patients. Figure 1 shows the analysis cohort and the data
available for analysis.
Inappropriate therapies
The inappropriate shock incidence for dual/triple-chamber
ICDs was 1.5% at 1 year (CI 1.0%–2.1%), 2.8% at 2 years
(CI 2.1%–3.8%), and 3.9% at 3 years (CI 2.8%–5.4%;
Figure 2A). Incidence of any inappropriate therapy in
dual-/triple chamber devices, including shock and/or ATP
therapy, was 2.3% at 1 year (CI 1.7%–3.1%), 3.7% at 2 years
(CI 2.8%–4.8%), and 5.7% at 3 years (CI 4.0%–7.6%;
Figure 2A). During the entire follow-up period, 48 of the
2019 patients with a dual-/triple-chamber device had 84
episodes with inappropriate shocks.
Single-chamber devices showed an inappropriate-shock
incidence of 2.5% at 1 year (CI 1.5%–3.9%) and 3.7% at
Table 1 Baseline characteristics
Subject characteristics
All patients
(N ¼ 2770)
Single-chamber
ICD (N ¼ 751)
Dual-chamber
ICD (N ¼ 948)
Triple-chamber
ICD (N ¼ 1071)
Demographics and clinical presentation
Geography (%)
North America 41 40 42 40
Europe 38 38 33 43
Other 21 22 25 17
Male (%) 79 81 79 78
Age (years) 65  12 62  12 63  13 68  11
Left ventricular ejection fraction (%) 32  13 33  14 36  15 28  9
QRS (ms) 126  33 107  22 114  27 153  28
Secondary prevention (%) 31 34 41 19
Device replacement or upgrade (%) 33 21 30 45
New York Heart Association functional class (%)
I 15 25 20 4
II 40 46 44 31
III 31 13 15 57
IV 1 1 0 2
No heart failure 13 15 21 4
History (%)
Cardiomyopathy, ischemic 44 43 45 43
Congestive heart failure 38 30 29 53
Coronary artery disease 45 47 44 45
Familial or inherited conditions with high
risk for ventricular tachycardia
5 5 6 3
Hypertension 52 46 54 55
Myocardial infarction 38 43 39 33
Valve dysfunction 25 18 21 33
Coronary artery bypass graft 24 21 22 27
Coronary artery intervention 28 30 30 24
Arrhythmias and conduction defects (%)
Atrial ﬁbrillation 30 22 27 37
Atrial ﬂutter 5 2 7 5
Atrial tachycardia 2 1 3 3
Ventricular tachycardia (including nonsustained) 36 34 47 27
Atrioventricular block 15 7 15 20
Left bundle branch block 25 6 9 53
Right bundle branch block 8 5 9 8
Medication (%)
Angiotensin-converting enzyme inhibitor or sartan 77 76 72 82
Beta-blocker 86 86 84 87
Diuretic 68 57 59 84
Calcium channel blocker 11 12 13 9
Statin 60 66 59 58
Antiarrhythmic drug 19 13 24 18
ICD ¼ implantable cardioverter-deﬁbrillator.
929Auricchio et al PainFree SST Trial Primary Results2 years (CI 2.2%–5.7%). Incidence of any inappropriate
single-chamber device therapy, including shock or ATP
therapy, was 3.4% at 1 year (CI 2.2%–5.0%) and 4.8% at
2 years (CI 3.2%–7.0%; Figure 2B). During the entire
follow-up period, 22 of 751 patients with a single-chamber
ICD had 31 episodes with inappropriate shocks.
The most frequent cause of an inappropriate shock was
AF for all device types, followed by oversensing due to
EGM noise (Table 2). The relationship between patient
baseline characteristics and the incidence of inappropriate
shocks at 2 years is shown in Figure 3. Multivariable analysis
identiﬁed a history of AF (hazard ratio [HR] 2.9, P¼ .0001),
history of VT (HR 2.2, P ¼ .001), and absence of prior
myocardial infarction (HR 2.3, P ¼ .009) as independent
predictors of inappropriate device shocks.VT zone shocks were enabled at the physician’s dis-
cretion in 1646 study patient (59% of the total). Typically,
VT detection required 24 consecutive R-R intervals (median,
quartiles: 16–24) to be r350 ms (median, quartiles: 340–
360 ms). Inappropriate shock incidence in patients with VT
shocks enabled was 2.8% at 2 years, which was not
signiﬁcantly different from the 3.4% inappropriate shock
incidence in the 41% of patients who did not have VT zone
shocks programmed (P ¼ .83; Figure 4).
There were 111 shocked episodes in 17 patients in whom
EGMs were overwritten due to limited device memory,
including patients with VT storms. If all shocked episodes
without reviewable EGMs were classiﬁed as inappropriate, the
inappropriate shock rate at 1 year would be 1.7% in dual/triple-
chamber ICD patients and 3.3% in single-chamber patients.
Enrollment Phase II (n=2544) 
Primary prevenon (n=1917) Secondary prevenon (n=847) 
Required programming 
Follow up visit every 6 months 
Enrollment Phase I (n=246) 
dual- or triple-chamber ICD  (n=2019) single-chamber ICD   (n=751) 
Follow up visit  at 1, 3, and 6 months 
Safety and detecon performance 
Not eligible (n=20) 
Figure 1 Flow diagram.
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There were 4028 episodes in which only appropriate therapies
were delivered, including 689 episodes in 234 patients who
received appropriate shocks and 3339 episodes in 363 patients
who received appropriate ATP only. The respective 1- and
2-year incidence rates of appropriate shocks were 5.9%
(CI 4.9%–7.1%) and 10.1% (CI 8.6%–11.7%) for the dual/
triple-chamber ICD group and 6.5% (CI 4.8%–8.5%) and 10.4%
(CI 7.8%–13.3%) for the single-chamber ICD group. For all
appropriate therapy (ie, both shocks and ATP), the respective
1- and 2-year incidence rates were 13.7% (CI 12.2%–15.3%) and
20.1% (CI 18.1%–22.1%) for the dual/triple-chamber ICD group
and 10.8% (CI 8.6%–13.3%) and 17.6% (CI 14.4%–21.2%) for
the single-chamber ICD group.
Combining appropriate and inappropriate therapies, the
all-cause therapy-free rate was 85.3% at 1 year (84.7% for
dual/triple-chamber ICD and 86.9% for single-chamber
ICD), and the all-cause shock free rate was 92.5% at 1 year
(92.8% for dual/triple-chamber ICD and 91.7% for single-
chamber ICD). Of note, of 804 episodes receiving shocks,
115 (14%) received any inappropriate shock.Mortality
In total, 230 patients died during the study. None of the
patients for whom device data were available died because of
inappropriately withheld device therapy or in relationship
with inappropriate therapy. The estimated mortality at 2
years was 10.2% (CI 8.7%–11.6%) in dual/triple-chamber
ICD patients [6.9% (CI 5.1%–8.7%) for dual-chamber ICD
and 13.0% (CI 10.7%–15.2%) for triple-chamber ICD] and
6.0% (CI 3.9%–8.0%) in single-chamber ICD patients.Sensitivity of discrimination algorithms
The discrimination algorithms withheld therapy for 9863
episodes. The ERC reviewed the 3339 episodes with EGM
for which therapy was withheld and considered therapy to be
appropriately withheld for 3291 episodes (98.6%). As
indicated earlier, the ERC also reviewed all treated episodes
and identiﬁed episodes with EGM that were true ventricular
arrhythmias for which therapy was delivered. The total
number of true ventricular arrhythmias was then 3901
episodes and relative sensitivity was 98.8%. None of the
48 sustained true ventricular arrhythmias for which therapy
was withheld led to death or major adverse events. In
addition, 13 episodes with detection delayed for more than
2 minutes did not have serious adverse consequences.
Discussion
The PainFree SST study demonstrated that novel ICD discrim-
ination algorithms and routine use of contemporary evidence-
based ICD programmingwill result in a low inappropriate shock
rate. Shock rates were uniformly low across a heterogeneous,
real-world population representing a variety of clinical ICD
device indications, treated with different types of ICDs (single-,
dual-, and triple-chamber ICDs), and afﬂicted by a multitude of
comorbidities including AF. Notably, the inappropriate shock
rate in our study was unaffected by physician-tailored treatment
of ventricular arrhythmias slower than 188 bpm.
Inappropriate ICD interventions
Implementation of a strategy that combines evidence-based
programming and enhanced discrimination algorithms may be
an effective way to reduce inappropriate and unnecessary ICD
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Figure 2 Inappropriate shocks and inappropriate therapy in dual/triple-chamber devices (A) and single-chamber devices (B). The main ﬁgure and the inset
show the same curves on a different scale in both panels.
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Table 2 Causes of inappropriate shocks
Dual/triple-chamber ICD Single-chamber ICD
Cause of inappropriate shock
No. of shocked
episodes (%)
No. of patients with
inappropriate shock(s)
No. of shocked
episodes (%)
No. of patients with
inappropriate shock(s)
Atrial ﬁbrillation/atrial ﬂutter 41 (49%) 26 25 (81%) 16
Other supraventricular tachycardia (eg, sinus
tachycardia, atrial tachycardia)
11 (13%) 8 3 (10%) 3
Committed shock after appropriate therapy 7 (8%) 7 0 (0%) 0
Ablation procedure 0 (0%) 0 1 (3%) 1
Electrogram noise 21 (25%) 6 2 (6%) 2
T-wave oversensing 4 (5%) 4 0 (0%) 0
Total 84 (100%) 48 31 (100%) 22
Patient counts are not mutually exclusive as some patients had shocks for multiple causes. Twenty-one patients had41 episode with inappropriate shocks
(maximum 8 episodes). In total, the 115 inappropriately shocked episodes received 220 shocks (maximum 6 shocks for a single episode).
No
Yes
Anti-Arrhythmic
No
Yes
Ventricular Tachycardia
No
Yes
Atrial Fibrillation
No
Yes
Myocardial infarction
No
Yes
Previous device
Primary prevention
Secondary prevention
Indication
< 120 ms
≥ 120 ms
QRS
≤ 30%
> 30%
LVEF
< 65 years
≥ 65 years
Age
Female
Male
Gender
dual/triple chamber
single chamber
Device type
Inappropriate shock incidence at 2 years (%)
0 1 2 3 4 5 6 7 8
Figure 3 Incidence of inappropriate shocks for subgroups. The vertical line at 3.1% represents the inappropriate shock rate at 2 years in the full study cohort.
LVEF ¼ left ventricular ejection fraction.
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propriate shock rates of 1.5% in the dual/triple-chamber ICD
group and 2.5% in the single-chamber ICD group. One-year
inappropriate therapy (ie, shocks and ATP) rates were 2.3% and
3.4% in the dual/triple-chamber ICD group and single-chamber
ICD group, respectively. To our knowledge, the inappropriate
shock and therapy rates demonstrated with this strategy are the
lowest reported in the literature. The 1-year inappropriate shock
rates of PainFree Rx II, EMPIRIC, and PREPARE were 9.3%,
10.7%, and 3.6%, respectively.3,16 MADIT-RIT reported a 5%
probability of inappropriate therapy in the delayed therapy arm
and a 4% probability of inappropriate therapy at 1 year of
follow-up in the high-rate therapy arm.9 Similarly, the
ADVANCE III study showed a 3% probability of inappropriate
shocks and 11.5% probability of inappropriate therapies at 1
year.10 Of note, in PainFree SST only 14% of shocked episodes
had any inappropriate shock. In comparison, the MADIT-RIT
study reported that the proportion of shocks that was inappro-
priate was 48% in the delayed therapy arm and 26% in the high-
rate arm.9 In Advance III, 40% of all shocks were inappropriate
in the standard-detection arm and 28% in the long-detection
interval arm.10 Our results are even more remarkable when we
consider the fact that MADIT-RIT did not include single-
chamber devices, which are generally less capable of with-
holding inappropriate therapy for atrial tachyarrhythmias.Causes of inappropriate shocks
Underlying causes of inappropriate ICD interventions include
supraventricular tachyarrhythmias (especially AF with rapid
ventricular response), lead or signal or noise oversensing, and
lead or connector malfunction.2,3 As in prior trials,8,9 AF wasthe most common cause of an inappropriate therapy, and a
baseline history of AF was a predictor of receiving an
inappropriate therapy. Our inappropriate therapy rate was
o3% at 1 year, despite a 30% prevalence of AF. In
comparison, the high-rate arm of MADIT-RIT reported a 1-
year inappropriate therapy rate of 5% despite an only 11%
prevalence of AF and a higher ICD therapy rate cutoffZ200
bpm with no SVT discriminators enabled. Our nearly 3-fold
higher prevalence of AF and lower rates of inappropriate
therapy in PainFree SST suggest to us the potential impor-
tance of applying discrimination algorithms at higher rates to
prevent unnecessary ICD interventions. A small minority of
patients in our study remained subject to inappropriate shocks
due to AF despite programming enhancements, so there
remains an appropriate role for both pharmacologic and
nonpharmacologic treatment measures in these patients.Use of multiple VT zones does not affect
inappropriate shock rate
In the MADIT-RIT trial, a VT zone with therapies was
programmed ON in the standard-interval detection group and
OFF in the high-rate group.9 The incidence of inappropriate
therapy in the standard-interval and high-rate groups after 2
years of follow-up were 25% and 6%, respectively. In the
PainFree SST study, the VT zone was recommended per
protocol to be programmed OFF, unless the patient had a
history of sustained VT or the physician considered it
appropriate to program it ON. In total, 59% of our patients
had VT zone shock therapies enabled, but without an
apparent increase in inappropriate shocks. It is reassuring
to note that the use of discrimination algorithms in
Heart Rhythm, Vol 12, No 5, May 2015934programmed VT zones did not result in any meaningful
difference in the inappropriate shock rate.
Study limitations
Some limitations of the PainFree SST trial deserve further
consideration. All patients enrolled in this study received
devices with proprietary discrimination algorithms produced
by a single manufacturer. Although the results may be
generalizable in the sense that a strategy of applying
discrimination algorithms to high ventricular rates, treating
only faster rhythms with longer duration, and using ATP
more aggressively may be used to minimize the risk of
inappropriate shocks, our results might prove speciﬁc to
patients with an ICD from this manufacturer. Some episode
EGMs were overwritten during VT/VF storms and conse-
quently lost to ﬁnal analysis. However, any such loss of
follow-up data was limited, and a sensitivity analysis
classifying all therapy episodes with missing EGMs as
inappropriate revealed no major impact on our primary
end-points or conclusions. Because the study end-point
was not mortality and in absence of a control group, no
strong claim on the cause of mortality can be made. Finally,
because of the absence of a control group in this design,
direct comparison to alternative shock reduction strategies
may be limited. We believe that the inclusive nature of the
study protocol allowed us to achieve a representative real-
world population.
Conclusion
Routine implementation of a predeﬁned (“out-of-the box”)
programming strategy in conjunction with the adoption of
novel discrimination algorithms led to a very low rate of
inappropriate shocks in ICD patients at 1 and 2 years.
Flexible programming of the VT zone did not affect the
inappropriate shock rate.
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Much focus has been placed recently on the prevention of unnecessary ICD shocks, both appropriate and inappropriate.
Strategies used to reduce shocks have included reprogramming to detect only faster rhythms that exceed a threshold
duration and providing antitachycardia pacing to painlessly terminate the arrhythmia without a shock. However, less
attention has been given to the nonprogrammable qualities of the arrhythmia discriminators in reducing shocks. Arrhythmia
discrimination algorithms play an important role in withholding inappropriate shocks after detection thresholds are met and
reducing the risk of an inappropriate shocks for patients with slower symptomatic ventricular tachycardia, which may
require deviation from evidence-based shock reduction programming. In the PainFree SST study, we demonstrated that the
combination of arrhythmia discrimination algorithms and evidence-based shock reduction programming results in very low
inappropriate shock rates. Furthermore, we demonstrated that the risk of an inappropriate shock is not increased when
therapies for slow VT are enabled, which occurred in 59% of enrolled subjects. The algorithms and programmed settings
used in the PainFree SST study were nominal settings for the ICDs used in the study, with the exception of the number of
intervals to detect ventricular ﬁbrillation. Thus, the shock reduction beneﬁt seen with the algorithms and programming in
this “real-world” clinical study can be easily extrapolated to the clinical setting, which in turn will beneﬁt patients by
reducing shocks and improving quality of life.
